

RETINOBLASTOMA SURVIVOR

TREATMENT SUMMARY

Care for Life

Patient Name
Date of Birth
Primary Doctor
This Summary Was Completed By
Name
Position
Hospital

GENERAL RETINOBLASTOMA INFORMATION

Diagnosis	
Date of Diagnosis:	DD/MMM/YYYY
Age at Diagnosis:	in weeks or months
Laterality:	☐ Left ☐ Right ☐ Bilateral ☐ Trilateral
Stage at Diagnosis:	Left: Right: IIRC, TNM or RE classification for each eye, if known
Ophthalmologis	st Details
Name:	
Hospital:	
Address:	
Telephone:	
Fax:	
Pager:	
Email:	
Oncologist Con	tact Details
Name:	
Hospital:	
Address:	
Telephone:	
Fax:	
Pager:	
Email:	

TREATMENT SUMMARY

Main Treatment Centre

Name:			
Key Contact:			
Position:			
Address:			
Telephone:			
Fax:			
Pager:			
Email:			
Secondary Trea	atment Centre (if shared care)	
Name:			
Key Contact:			
Position:			
Address:			
Telephone:			
Fax:			
Pager:			
Email:			
Key Treatment	Dates		
Initial Treatment:	Start: DD/MMM/YYYY	End: DD/MMM/YYYY	
First Relapse:	DD/MMM/YYYY		
Treatment:	Start: DD/MMM/YYYY	End: DD/MMM/YYYY	

Second Relapse:	DD/MMM/YYYY						
	DD/IVIIVIIVI/YYYY						
Treatment:	Start: DD/MMM/YYYY	End: DD/MMM/YYYY					
Third Relapse:	DD/MMM/YYYY						
Treatment:	Start: DD/MMM/YYYY	End: DD/MMM/YYYY					
Fourth Relapse:	DD/MMM/YYYY						
Treatment:	Start: DD/MMM/YYYY	End: DD/MMM/YYYY					
Enucleation Sur	rgery – Left Eye						
Date of Surgery:	DD/MMM/YYYY	Surgeon:					
Hospital:							
Implant Inserted:	☐ Yes ☐ No						
Type of Implant:							
Pathology:	☐ Negative ☐ O	ptic nerve Choroid/sclera					
Pathology Staging:	TNM classification, if known						
Enucleation Surgery – Right Eye							
Date of Surgery:	DD/MMM/YYYY	Surgeon:					
Hospital:							
Implant Inserted:	☐ Yes ☐ No						
Type of Implant:							
Pathology:	☐ Negative ☐ O	ptic nerve Choroid/Sclera					
Pathology Staging:	TNM classification, if known		_				

Central Venous Catheter

Type of Line:	☐ Port		External Line	Other:	
Date of Surgery:	DD/MMM/YY	YY			
Surgeon:					
Hospital:					
Complications:					
Date of Removal:	DD/MMM/YY	YY			
Chemotherapy					
Clinical Trial Name	<u></u>				
Clinical Trial #:					
Main Investigator:					
Protocol Attached:	☐ Yes		No		
Number of Cycles:					
Drug Name	Da	ites		Dose	Method of Delivery

Radiotherapy

Date of Treatment:	DD/MMM/YYYY	
Treatment Centre:	,	
Key Contact:		
Position:		
Fax:		
Pager:		
Email:		
Clinical Trial Name:		
Clinical Trial #:		
Main Investigator:		
Protocol Attached:	☐ Yes ☐ No	
Area Treated:	□ L Eye □ R Eye	☐ Both ☐ Orbital
Type:	☐ Whole Eye ☐ Ler	ns Sparing
# of Sessions:		Total Dose:
Age at treatment:		
Radioactive pla	que	
Dates:	Inserted: DD/MMM/YYYY	Removed: DD/MMM/YYYY
Eye Treated:	☐ Left ☐ Right	☐ Both
Туре:	☐ Iodine-125 ☐ Ru	thenium-106
Total Dose:		Age at treatment:

Stem Cell Transplant

Date of Transplant:	DD/MMM/YYYY		
Transplant Centre:			
Transplant Doctor:			
Address:			
Telephone:			
Fax:			
Pager:			
Email:			
Clinical Trial Name:			
Clinical Trial #:			
Main Investigator:			
Protocol Attached:	□ Yes □ No		
Type:	☐ Autologous ☐	Allogenic \Box	Syngenic
Conditioning Therap	ру		
Chemo Drug Name	Dates	Dose	Method of Delivery
Radiotherapy	Dates	Total Dose	Treatment Centre

Complications / Long Term Side Effects

Complication	Date Diagnosed	Treatment	Treating Physician

Recommended Follow Up

B.M.A.:

	cans and other x-rays are not recommended for routine imaging lren with a known or suspected constitutional RB1 mutation.
E.U.A.:	
Retinal Office	Exams:
Oncology:	
M.R.I.:	
L.P.:	

Notes			

For further information about retinoblastoma, visit World Eye Cancer Hope online at

www.wechope.org

